The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.m

Sarcoid-like granulomatosis (endo-/extrathoracic)

Examination of the skin including tatoos and scars for granulomas can be rewarding

Publications

Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM

Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2018 09;41;336-339 — 2018 09 — 336-339

Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy.

JAAD case reports 2016 May;2;264-8 — 2016 May — 264-8

Andersen R, Nørgaard P, Al-Jailawi MK, Svane IM

Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab.

Oncoimmunology 2014;3;e954506 — 2014 — e954506

Murphy KP, Kennedy MP, Barry JE, O'Regan KN, Power DG

New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.

Oncology research and treatment 2014;37;351-3 — 2014 — 351-3

Reule RB, North JP

Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab.

Journal of the American Academy of Dermatology 2013 Nov;69;e272-e273 — 2013 Nov — e272-e273

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Sc

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

PloS one 2013;8;e53745 — 2013 — e53745

Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H, Neyns B

Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.

Anticancer research 2012 Apr;32;1355-9 — 2012 Apr — 1355-9